AlphaValue/Baader Europe Cuts Diasorin Price Target, Forecasts Amid Challenges to Near-term Earnings

09:20 AM EST, 12/30/2025 (MT Newswires) -- AlphaValue/Baader Europe revised its price target and financial forecasts for Diasorin (DIA.MI), taking into account the Italian medical diagnostics company's updated guidance for full-year 2025. On Tuesday, the buy-rated stock's price target was lowered to 111 euros from 118 euros. The research firm also cut its projected EPS for 2025 and 2026 by 12.6% and 7.64%, respectively, to 3.42 euros and 4.12 euros, citing unfavorable market conditions resulting in near-term challenges for the company's earnings. "Despite revising our estimates and target price downward, DiaSorin remains a compelling investment opportunity. This is underpinned by strong business prospects, including the recent approval of LIAISON NES for point-of-care testing in the US, a $3bn market," analysts wrote. "The company's continued success in its US hospital strategy and ongoing innovation, further bolster its investment appeal."